You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 297 No. 15, April 18, 2007 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Aging/ Geriatrics
 •Men's Health
 •Prostate Disease
 •Oncology
 •Prostate Cancer
 •Statistics and Research Methods
 •Prognosis/ Outcomes
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Outcomes of Treatment vs Observation of Localized Prostate Cancer in Elderly Men

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Wong and colleagues1 report a survival advantage in elderly men with low- and intermediate-risk prostate cancer who undergo active treatment compared with those who are observed. I believe that these results should be interpreted with caution.

In the active treatment cohort, 42% of the men underwent prostatectomy, the only group in which pathologic stage was available. Since the SEER database records the pathologic stage when available, these men were classified as low- or intermediate-risk based on pathologic staging. Similarly, these patients were classified as low- or intermediate-risk based on pathologic Gleason score. Nonsurgical patients were classified by clinical stage and biopsy Gleason score.

Pathologic upstaging and upgrading are common events at prostatectomy. During the early time period of the study by Wong et al, it was reported that 40% of clinical stage T1c (prostate-specific antigen-detected) cancers and 57% of clinical stage T2 (palpable) tumors were upstaged . . . [Full Text of this Article]

Michael P. Porter, MD, MS
mporter@u.washington.edu
Department of Urology
University of Washington
Seattle



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

RELATED LETTERS

Outcomes of Treatment vs Observation of Localized Prostate Cancer in Elderly Men
Grace L. Lu-Yao, Michael J. Barry, Peter C. Albertsen, and Siu-Long Yao
JAMA. 2007;297(15):1651.
EXTRACT | FULL TEXT  

Outcomes of Treatment vs Observation of Localized Prostate Cancer in Elderly Men
Mark C. Scholz, Richard Y. Lam, and Laurence Klotz
JAMA. 2007;297(15):1651-1652.
EXTRACT | FULL TEXT  

Outcomes of Treatment vs Observation of Localized Prostate Cancer in Elderly Men
George A. Mark
JAMA. 2007;297(15):1652.
EXTRACT | FULL TEXT  

Outcomes of Treatment vs Observation of Localized Prostate Cancer in Elderly Men—Reply
Yu-Ning Wong, Nandita Mitra, Gary Hudes, J. Sanford Schwartz, Fei Wan, Chantal Montagnet, and Katrina Armstrong
JAMA. 2007;297(15):1652-1653.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Survival Associated With Treatment vs Observation of Localized Prostate Cancer in Elderly Men
Yu-Ning Wong, Nandita Mitra, Gary Hudes, Russell Localio, J. Sanford Schwartz, Fei Wan, Chantal Montagnet, and Katrina Armstrong
JAMA. 2006;296(22):2683-2693.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.